XML 33 R21.htm IDEA: XBRL DOCUMENT
v3.24.1.1.u2

Net Loss Per Share | 3 Months Ended
--- | ---
Mar. 31, 2024
Earnings Per Share [Abstract] |
Net Loss Per Share | Note 15 — Net Loss Per Share The Net loss per share - attributable to PAVmed Inc. - basic and diluted and Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted - for the respective periods indicated - is as follows: Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share
|  | 2024 |  |  | 2023 |
|  | Three Months Ended March 31, |
|  | 2024 |  |  | 2023 |
Numerator |  |  |  |  |  |  |  |
Net loss - before noncontrolling interest |  | $ | (18,512 | ) |  | $ | (22,214 | )
Net loss attributable to noncontrolling interest |  |  | 3,300 |  |  |  | 4,283 |
Net loss - as reported, attributable to PAVmed Inc. |  | $ | (15,212 | ) |  | $ | (17,931 | )
Series B Convertible Preferred Stock dividends – earned |  | $ | (80 | ) |  | $ | (74 | )
Deemed dividend on Subsidiary Preferred Stock attributable to the noncontrolling interests |  | $ | (7,496 | ) |  | $ | — |
Net loss attributable to PAVmed Inc. common stockholders |  | $ | (22,788 | ) |  | $ | (18,005 | )
Denominator |  |  |  |  |  |  |  |
Weighted average common shares outstanding, basic and diluted |  |  | 8,694,904 |  |  |  | 6,473,010 |
Net loss per share (1) |  |  |  |  |  |  |  |
Basic and diluted |  |  |  |  |  |  |  |
Net loss attributable to PAVmed Inc. common stockholders |  | $ | (2.62 | ) |  | $ | (2.78 | )
(1) | - Convertible Preferred Stock would potentially be considered a participating security under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and as such holders are not contractually obligated to share in the losses, there is no impact on the Company’s net loss per share calculation for the periods indicated.
The common stock equivalents have been excluded from the computation of diluted weighted average shares outstanding as their inclusion would be anti-dilutive, are as follows: The Series B Convertible Preferred Stock dividends earned as of each of the respective years noted, are included in the calculation of basic and diluted net loss attributable to PAVmed common stockholders for each respective period presented. Notwithstanding, the Series B Convertible Preferred Stock dividends are recognized as a dividend payable only upon the dividend being declared payable by the Company’s board of directors. Note 15 — Net Loss Per Share - continued Basic weighted-average number of shares of common stock outstanding for the three month periods ended March 31, 2024 and 2023 include the shares of the Company issued and outstanding during such periods, each on a weighted average basis. The basic weighted average number of shares of common stock outstanding excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. However, as the Company was in a loss position for all years presented, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive. The common stock equivalents excluded from the computation of diluted weighted average shares outstanding are as follows: Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share
|  | 2024 |  |  | 2023 |
|  | March 31, |
|  | 2024 |  |  | 2023 |
Stock options and restricted stock awards |  |  | 1,704,460 |  |  |  | 1,263,715 |
Series Z Warrants |  |  | 795,830 |  |  |  | 795,830 |
Series B Convertible Preferred Stock |  |  | 88,756 |  |  |  | 81,993 |
Total |  |  | 2,589,046 |  |  |  | 2,141,538 |
The total stock options and restricted stock awards are inclusive of 60,054 and 33,391 stock options as of March 31, 2024 and 2023, respectively; granted outside the PAVmed 2014 Equity Plan.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration